Ilsung Pharmaceuticals Overview
- Founded
-
1961

- Status
-
Public
- Employees
-
228

- Stock Symbol
-
003120

- Share Price
-
$70.10
- (As of Friday Closing)
Ilsung Pharmaceuticals General Information
Description
Ilsung Pharmaceuticals Co Ltd is a South Korea based company engages in the development, manufacture, and sale of pharmaceutical products. It offers antibiotics; diagnostics, including contrast media; and products for cardiovascular, GI tract, metabolism disorders, ophthalmological disorders, and inhalation anesthetics.
Contact Information
Website
www.ilsung-ph.co.kr
Formerly Known As
Ilsung Corporation
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
KRX
Primary Office
- 84-gil 9 Wonhyo-ro Yongsan-ku
- Seoul
- South Korea
+82 00-0000-0000
Ilsung Pharmaceuticals Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$70.10 | $69.89 | $55.86 - $104.89 | $104M | 1.48M | 4.41K | $57.34 |
Ilsung Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | (145,687) | 41,417 | 75,202 | 63,955 |
Revenue | 45,418 | 36,746 | 34,387 | 41,517 |
EBITDA | 43,171 | 1,102 | 5,755 | 9,940 |
Net Income | 85,825 | (1,194) | 2,727 | 5,762 |
Total Assets | 345,702 | 312,081 | 340,286 | 319,002 |
Total Debt | 238 | 152 | 405 | 109 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ilsung Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Ilsung Pharmaceuticals Patents
Ilsung Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-1931330-A1 | Composition comprising tanshinone compounds isolated from the extract of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and the use thereof | Inactive | 06-Oct-2005 | 0000000000 | |
US-20090312413-A1 | Composition comprising tanshinone compounds isolated from the extract of salviae miltiorrhizae radix for treating or preventing cognitive dysfunction and the use thereof | Inactive | 06-Oct-2005 | 0000000000 |
Ilsung Pharmaceuticals Executive Team (1)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Seok geun Yoon | Chief Executive Officer |